Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to 6.07%.

  • Eton Pharmaceuticals' EBITDA Margin fell 110000.0% to 6.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.89%, marking a year-over-year increase of 42400.0%. This contributed to the annual value of 6.66% for FY2024, which is 28900.0% down from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' EBITDA Margin is 6.07%, which was down 110000.0% from 7.79% recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' EBITDA Margin ranged from a high of 45.08% in Q1 2021 and a low of 754.45% during Q3 2021
  • Its 5-year average for EBITDA Margin is 63.36%, with a median of 7.8% in 2023.
  • Data for Eton Pharmaceuticals' EBITDA Margin shows a peak YoY increase of 226141900bps (in 2021) and a maximum YoY decrease of 2000000000bps (in 2021) over the last 5 years.
  • Over the past 5 years, Eton Pharmaceuticals' EBITDA Margin (Quarter) stood at 21.57% in 2021, then crashed by -42bps to 12.5% in 2022, then crashed by -154bps to 6.69% in 2023, then soared by 181bps to 5.4% in 2024, then tumbled by -212bps to 6.07% in 2025.
  • Its EBITDA Margin stands at 6.07% for Q3 2025, versus 7.79% for Q2 2025 and 26.32% for Q1 2025.